{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:43Z","timestamp":1792039603634,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109627","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:41:05Z","timestamp":1789944065000},"page":"109627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study"],"prefix":"10.1016","volume":"221","author":[{"given":"Arnaud","family":"De Gunten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mogenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bronstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Pollien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Le Floch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Pluvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Paleiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bylicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109627_b0005","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. . CA Cancer J Clin. may 202DOI: 10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.lungcan.2026.109627_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics","author":"Cheng","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00428-4","article-title":"Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study","author":"Luo","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lungcan.2026.109627_b0020","doi-asserted-by":"crossref","unstructured":"Debieuvre D, C. Locher, L. Falchero, et al. Vingt ans d\u2019\u00e9pid\u00e9miologie des cancers broncho-pulmonaires diagnostiqu\u00e9s dans les h\u00f4pitaux non-universitaires fran\u00e7ais, l\u2019\u00e9tude KBP-2020-CPHG compar\u00e9e aux \u00e9ditions 2000 et 2010. Revue des maladies respiratoires. 2022. DOI:10.1016\/j.rmra.2021.11.038.","DOI":"10.1016\/j.rmra.2021.11.038"},{"key":"10.1016\/j.lungcan.2026.109627_b0025","unstructured":"Institut national du cancer. . Panorama des cancers en France. Edition 2024. https:\/\/www.cancer.fr\/catalogue-des-publications\/panorama-des-cancers-en-france-edition-2024."},{"key":"10.1016\/j.lungcan.2026.109627_b0030","doi-asserted-by":"crossref","unstructured":"Joan H. Schiller, M.D et al. Comparison of Four Chemotherapy Regimens for Advanced Non\u2013Small-Cell Lung Cancer. New England Journal of Medicine. jan 2002. DOI: 10.1056\/NEJMoa011954.","DOI":"10.1056\/NEJMoa011954"},{"key":"10.1016\/j.lungcan.2026.109627_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","author":"Fehrenbacher","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2026.109627_b0040","doi-asserted-by":"crossref","unstructured":"Hossein Borghaei, D.O et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer. New England J Med. 2015. DOI: 10.1056\/NEJMoa1507643.","DOI":"10.1056\/NEJMoa1507643"},{"key":"10.1016\/j.lungcan.2026.109627_b0045","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","author":"Prof Roy","year":"2016","journal-title":"The Lancet."},{"key":"10.1016\/j.lungcan.2026.109627_b0050","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","author":"Achim Rittmeyer","year":"2017","journal-title":"The Lancet."},{"key":"10.1016\/j.lungcan.2026.109627_b0055","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2040\u20132051","key":"10.1016\/j.lungcan.2026.109627_b0060","first-page":"2018","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2026.109627_b0065","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0070","doi-asserted-by":"crossref","unstructured":"RECK et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non\u2013Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2021 50%. 2021. DOI: 10.1200\/JCO.21.00174.","DOI":"10.1200\/JCO.21.00174"},{"key":"10.1016\/j.lungcan.2026.109627_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2024.05.002","article-title":"5-Year real-world outcomes with frontline pembrolizumab monotherapy in PD-L1 expression \u2265 50% advanced NSCLC","author":"Velcheti","year":"2024","journal-title":"Clinical Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109627_b0080","article-title":"Five year overall survival for patients with advanced non-small cell lung cancer treated with pembrolizumab. Results from the phase I KEYNOTE 001 Study","author":"Garon eb,","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2026.109627_b0085","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: A nationwide retrospective cohort study","volume":"43","author":"Rousseau","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lungcan.2026.109627_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","author":"Sun","year":"2023","journal-title":"Jama Oncol."},{"key":"10.1016\/j.lungcan.2026.109627_b0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0100","doi-asserted-by":"crossref","unstructured":"Storme et al. Prescription de l\u2019immunoth\u00e9rapie chez les patients \u00ab\u00a0long-r\u00e9pondeurs\u00a0\u00bbManagement of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response. 2022. DOI: 10.1016\/j.rmr.2022.06.006.","DOI":"10.1016\/j.rmr.2022.06.006"},{"key":"10.1016\/j.lungcan.2026.109627_b0105","article-title":"ESMO clinical practice guideline for metastatic non-small-cell lung cancer","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0110","article-title":"Spending, utilization, and price trends for immune checkpoint inhibitors in US Medicaid programs: An empirical analysis from 2011 to 2021","volume":"2023","author":"Shin","year":"2011","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.lungcan.2026.109627_b0115","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories JAMA from 2020 to 2050","author":"Chen","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0120","article-title":"Immune-related adverse events after 2 years in patients with advanced non-small-cell lung cancer receiving extended immune checkpoint inhibitor therapy","author":"Elghawy","year":"2024","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0125","article-title":"Late immune-related adverse events after at least two years of immune checkpoint inhibitor therapy: incidence and association with survival in patients with advanced NSCLC","author":"Elghawy","year":"2025","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2026.109627_b0130","doi-asserted-by":"crossref","unstructured":"Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of Non\u2013Small-Cell Lung Cancer. Lung. Mar 2025. DOI: 10.1007\/s00408-025-00801-x.","DOI":"10.1007\/s00408-025-00801-x"},{"key":"10.1016\/j.lungcan.2026.109627_b0135","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-021-03114-z","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","author":"Bilger","year":"2022","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.lungcan.2026.109627_b0140","doi-asserted-by":"crossref","unstructured":"Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland G, Chandra S, Chmielowski B, DiMaio D, Dronca R, Fields RC, Fleming MD, Galan A, Guild S, Hyngstrom J, Karakousis G, Kendra K, Kiuru M, Lange JR, Lanning R, Logan T, Olson D, Olszanski AJ, Ott PA, Ross MI, Rothermel L, Salama AK, Sharma R, Skitzki J, Smith E, Tsai K, Wuthrick E, Xing Y, McMillian N, Espinosa S. NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024. J Natl Compr Canc Netw. 2024. DOI: 10.6004\/jnccn.2024.0036.","DOI":"10.6004\/jnccn.2024.0036"},{"key":"10.1016\/j.lungcan.2026.109627_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmr.2023.07.002","article-title":"Les maladies oligom\u00e9tastatiques\u00a0: \u00e9tat actuel et perspectives dans les cancers bronchiques non \u00e0 petites cellules","author":"Berghmans","year":"2023","journal-title":"Rev maladies respiratoires"},{"key":"10.1016\/j.lungcan.2026.109627_b0150","doi-asserted-by":"crossref","unstructured":"Mogenet et al. Recommandations de la prise en charge des CBNPC oligom\u00e9tastatiques. Bull Cancer (Paris). march 2025. DOI: 10.1016\/S0007-4551(25)00162-6.","DOI":"10.1016\/S0007-4551(25)00162-6"},{"key":"10.1016\/j.lungcan.2026.109627_b0155","doi-asserted-by":"crossref","unstructured":"Sriram Vaidyanathan et al. FDG PET\/CT in infection and inflammation\u2014current and emerging clinical applications. jul 2015. DOI: 10.1016\/j.crad.2015.03.010.","DOI":"10.1016\/j.crad.2015.03.010"},{"key":"10.1016\/j.lungcan.2026.109627_b0160","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.212481","article-title":"18F FDG PET\/CT and novel molecular imaging for directing immunotherapy in cancer","author":"Hughes","year":"2022","journal-title":"Radiology."},{"key":"10.1016\/j.lungcan.2026.109627_b0165","doi-asserted-by":"crossref","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. mar 2017. DOI: 10.1016\/S1470-2045(17)30074-8.","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"10.1016\/j.lungcan.2026.109627_b0170","doi-asserted-by":"crossref","unstructured":"Pandey et al, Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review, Springer Nature, Sept 2025. DOI:10.1007\/s00262-025-04143-8.","DOI":"10.1007\/s00262-025-04143-8"},{"key":"10.1016\/j.lungcan.2026.109627_b0175","unstructured":"Intergroupe Francophone de Canc\u00e9rologie Thoracique. . Synopsis ETUDE IFCT-2103 DIAL. 2020. https:\/\/www.ifct.fr\/images\/IFCT-2103_synopsis_V1.0_20211220.pdf."},{"issue":"v658","key":"10.1016\/j.lungcan.2026.109627_b0180","first-page":"2019","volume":"30","author":"Zalcman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2026.109627_b0185","unstructured":"Institut national du cancer. Etude PULSE\u00a0: \u00e9tude de non-inf\u00e9riorit\u00e9 de phase 3, randomis\u00e9e \u00e9valuant le pembrolizumab comme traitement d\u2019entretien \u00e0 dose conventionnelle ou adapt\u00e9e, chez des patients atteints d\u2019un cancer du pumon non \u00e9pidermo\u00efde. 2023. https:\/\/www.cancer.fr\/personnes-malades\/registre-des-essais-cliniques\/etude-pulse-etude-de-non-inferiorite-de-phase-3-randomisee-evaluant-le-pembrolizumab-comme-traitement-d-entretien-a-dose-conventionnelle-ou-adap."},{"key":"10.1016\/j.lungcan.2026.109627_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.13063","article-title":"Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients","author":"Marolleau","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109627_b0195","doi-asserted-by":"crossref","unstructured":"Vanita NORONHA et al. Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). J Clin Oncol. may 2025. DOI: 10.1200\/JCO-25-01546.","DOI":"10.1200\/JCO-25-01546"},{"key":"10.1016\/j.lungcan.2026.109627_b0200","doi-asserted-by":"crossref","unstructured":"Celine HOYEK et al. Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review. JCO Global Oncology. mar 2025. DOI: 10.1200\/GO-24-00409.","DOI":"10.1200\/GO-24-00409"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:07Z","timestamp":1792037347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"alternative-id":["S0169500226006884"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109627","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109627"}}